Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity

Abstract

Oridonin, as a natural terpenoids found in traditional Chinese herbal medicine Isodon rubescens (Hemsl.) H.Hara, is widely present in numerous Chinese medicine preparations. The purpose of this review focuses on providing the latest and comprehensive information on the pharmacology, pharmacokinetics and toxicity of oridonin, to excavate the therapeutic potential and explore promising ways to balance toxicity and efficacy of this natural compound. Information concerning oridonin was systematically collected from the authoritative internet database of PubMed, Elsevier, Web of Science, Wiley Online Library and Europe PMC applying a combination of keywords involving “pharmacology,” “pharmacokinetics,” and “toxicology”. New evidence shows that oridonin possesses a wide range of pharmacological properties, including anticancer, anti-inflammatory, hepatorenal activities as well as cardioprotective protective activities and so on. Although significant advancement has been witnessed in this field, some basic and intricate issues still exist such as the specific mechanism of oridonin against related diseases not being clear. Moreover, several lines of evidence indicated that oridonin may exhibit adverse effects, even toxicity under specific circumstances, which sparked intense debate and concern about security of oridonin. Based on the current progress, future research directions should emphasize on 1) investigating the interrelationship between concentration and pharmacological effects as well as toxicity, 2) reducing pharmacological toxicity, and 3) modifying the structure of oridonin—one of the pivotal approaches to strengthen pharmacological activity and bioavailability. We hope that this review can provide some inspiration for the research of oridonin in the future.

Introduction

Oridonin, (PubChem CID: 5321010, CAS No: 28957-04-2, MW: 364.4 g/mol), with the molecular formula of C₂₀H₂₈O₆ (Cheng et al., 2019), is a naturally occurring terpenoids that mainly exists in Isodon rubescens (Hemsl.) H.Hara (Figure 1; Yang I.-H. et al., 2017; Jian et al., 2019; Meng et al., 2019). In thousands of years of clinical practice, the Isodon rubescens (Hemsl.) H.Hara has been widely applied as central agent in classic traditional Chinese medicine (TCM) formulas with its efficacy of clearing away heat and detoxifying, boosting blood circulation and alleviating pain. Generally, I. rubescens (Hemsl.) H.Hara is frequently utilized in the treatment of acute and chronic pharyngitis, tonsillitis and bronchitis in clinic (Zhang et al., 2020). As the main bioactive chemical component of I. rubescens (Hemsl.) H.Hara, in recent years, numerous achievements have been witnessed on the exploration of pharmacological effects of oridonin, such as anti-inflammatory (Cummins et al., 2019; He et al., 2019), anti-cancer (Vasaturo et al., 2018; Jeon et al., 2019; Hu et al., 2020), anti-microbial (Li D. et al., 2016), anti-sepsis (Zhao et al., 2016), neuroprotection (Lin et al., 2019), immunoregulation (Guo et al., 2013) and so on. Consequently, to some extent, these rapid advancements in the discovery of the pharmacological activity of oridonin have provided extensive opportunities for the development of innovative disease strategies. On the other hand, there have been mounting reports concentrated on the adverse reactions of oridonin. Recent studies have shown that oridonin can cause suicidal erythrocyte death, induce the expression and activation of CYP2C and CYP3A family, and interfere with the early embryonic development of zebrafish. Under this background, thereby motivated, we herein to summarize the latest and comprehensive information on the pharmacology, toxicity and pharmacokinetics of oridonin, to excavate the potential of this natural active ingredient in the treatment of various diseases and furnish basic information for the rational and secure utilization of oridonin.

FIGURE 1

Pharmacology

Anti-Inflammatory Activity

According to the literature, oridonin can markedly inhibit experimental autoimmune neuritis (EAN) by lessening local inflammatory reaction and increasing the proportion of immune regulating macrophages in the peripheral nerves possibly by the pathway of Notch, which indicates that it can be developed as a potential therapeutic agent for human Guillain-Barre syndrome (GBS) and neuropathies (Xu L. et al., 2019). Moreover, the employment of oridonin enables to relieve carrageenan-induced pleurisy through activating the KEAP-1/Nrf2 pathway and suppressing the TXNIP/NLRP3 and NF-κB pathway in the model of BALB/c mice. These specific manifestations includes reducing lung injury scores, releasing of cytokines, neutrophil infiltration, exudating volume and the exudate protein concentration, decreasing the levels of oxidative stress markers (Yang et al., 2020). Recently, researcher relies on the fact that oridonin itself can act as a protective agent against LPS-induced inflammatory response, which the specific mechanisms involve in ROS accumulation, JNK activation, nuclear translocation of NF-κB (Huang et al., 2020). Oridonin also inhibits autophagy and survival in rheumatoid arthritis fibroblast-like synoviocytes (He et al., 2020). In addition, oridonin can also resist a series of inflammatory reactions including LPS-induced inflammation in human gingival fibroblasts (Yu et al., 2019), IL-1β-induced inflammation in human osteoarthritis chondrocytes (Jia et al., 2019) and LPS-induced endometritis (Zhou et al., 2019). These findings indicate that oridonin may be served as a potential therapeutic agent for a variety of inflammatory related diseases. A great deal of immune cells including T cells plays an important role in the process of inflammation. In recent years, studies on anti-inflammatory effect of oridonin based on immune response have gradually increased. Research showed that it alleviated the colitis induced by trinitrobenzene sulfonic acid as represented by a decrease in colonic interferon-/inteleukin-17 secretion and a consumption in splenic Th1/Th17 cells and effector memory CD4(+) T cells (Wang et al., 2015). In addition, oridonin inhibited inflammatory graft rejection by depleting a great number of T cells in spleen and peripheral blood (Guo et al., 2013).

Anticancer Activity

The efficacy of mainstay cancer therapies such as cytotoxics and radiation, has reached a plateau in the treatment of multiple cancers. In this regard, there is an urgent sense that ameliorations must now come from fresh approaches. In recent years, continuous attention is also shifting to the development of natural anti-tumor agents. Oridonin has a variety of documented anti-cancer activities such as its ability to against gastric cancer (He et al., 2017), oral cancer (Yang Y.-C. et al., 2017), nasopharyngeal carcinoma (Liu et al., 2021), esophageal cancer (Jiang et al., 2019), ovarian cancer (Dong et al., 2018), leukemia (Li and Ma, 2019; Zhang D. et al., 2019), and myeloma (Wu et al., 2020), etc. Its main mechanism involves in inhibiting proliferation (Hao et al., 2016), inducing apoptosis (Gu et al., 2015; Clayton et al., 2016; Qing et al., 2016; Xu et al., 2016) and autophagy (Tiwari et al., 2015; Yao et al., 2017), suppressing migration and invasion (Li Y.-C. et al., 2016), reversing drug resistance (Kadioglu et al., 2018)] and so on.

As documented in literature, utilization of oridonin increased the level of E-cadherin and ALP, reduced the vimentin, phospho-FAK levels, snail, slug, and LDH in human small cell lung cancer cell line H1688 with concentration of 2.5, 5, 10, 20, and 40 µM for 24 and 48 h in vitro. Of course, the author also confirmed the anti-lung cancer effect of oridonin in the model of BALB/c nude mice (Xu et al., 2020). Another study on the anti-lung cancer of oridonin proved that, oridonin sensitized cisplatin-induced apoptosis via AMPK/Akt/mTOR-dependent autophagosome accumulation in A549 Cells (Yang et al., 2019a). Moreover, it augmented the radiosensitivity of lung cancer cells by up-regulating Bax and down-regulating Bcl-2 (Li C. et al., 2018), underpinned radiation-induced cell death by accelerating DNA damage in non-small cell lung cells (Park et al., 2018) and promoted G₂/M arrest in A549 cells by facilitating ATM (Zheng et al., 2017). In the aspect of anti-breast cancer, oridonin could synergistically enhance the anti-tumor effect of doxorubicin on aggressive breast cancer by promoting apoptosis and anti-angiogenesis (Li et al., 2019). Besides, this compound could inhibit angiogenesis and EMT related to VEGF-A (Li C. Y. et al., 2018), block Notch signaling pathway to inhibit the growth and metastasis of breast cancer (Xia et al., 2017), and induce autophagy to promote apoptosis (Li and Yang, 2015). In addition to its above anti-tumor effects, there is growing evidences that oridonin exhibits other anti-tumor activities such as colorectal cancer (Bu H. et al., 2019), pancreatic cancer (Liu D. et al., 2020), gallbladder cancer (Chen, et al., 2019), prostate cancer (Lu et al., 2017) and so on. Given that pathway defects have been recognized by most chemotherapies, oridonin may be a logical botanical for future researches of tumor adjuvant therapy. Figure 2 gives the antitumor mechanism of oridonin.

FIGURE 2

Hepatorenal Protective Activity

With the deepening of the research, the hepatorenal protective activity of oridonin has been gradually recognized. In a report on the research of LPS/D-galactosamine-induced acute liver injury in mice, oridonin was used as a compound known to be effective at improving the survival rate, alleviating histopathological abnormalities, and suppressing plasma aminotransferases, which the mechanisms may involve in the suppression of pro-apoptotic cytokine TNF-α and JNK-associated pro-apoptotic signaling (Deng et al., 2017). Oridonin also ameliorated carbon tetrachloride-induced liver fibrosis in mice through inhibiting the NLRP3 inflammasome (Liu D.-L. et al., 2020). Mouse immortalized stellate cell line JS1 treated with oridonin at the concentration of 5, 10, and 15 µM showed that it significantly impede posttranslational modifications of IRAK4 in the TLR4 signaling pathway (Shi et al., 2019). In addition, the inhibition of LPS induced apoptosis promoting cytokines IL-1 β, IL-6, and MCP-1, as well as ICAM-1 and VCAM-1 observed in LX-2 cells also appear to be able to validate the protective effect of oridonin on liver (Cummins et al., 2018). In terms of kidney protection, oridonin alleviated IRI-induced kidney injury by suppressing inflammatory response of macrophages through AKT-related pathways (Yan et al., 2020). Furthermore, oridonin at the concentrations of 2.5, 5, 10, and 20 µM managed to alleviate albuminuria, improve renal function and attenuate renal histopathological injury, hinder inflammatory cytokine production, down-regulate TLR4 expression and inhibit NF-κB and p38-MAPK activation, with the effects augmented as the dose increased (Li J. et al., 2018). These studies may provide a new recognition of natural medicine for the treatment of liver and kidney diseases.

Cardioprotective Activity

Diseases associated with cardiovascular diseases are an increasing problem in most parts of the world and, as with many other problems of today, are becoming more and more urgent for people all over the world. Therefore, a reasonable and effective strategy and approach is now essential to fight against this malady. As reported by researches in recent years, oridonin exhibited beneficial influences on cardiovascular disease. In a myocardial ischemia-reperfusion injury mouse models, down-regulation of oxidative stress and NLRP3 inflammation has been shown to mitigative effect of oridonin to myocardial ischemia reperfusion injury (Lu et al., 2020). Similar results have been verified by researchers from the perspective of metabonomics (Zhang J. et al., 2019). Oxidative stress, which has a critical link with the development of cardiac hypertrophy and heart failure, can reportedly be inhibited by oridonin via mitigating pressure overload-induced cardiac hypertrophy and fibrosis, preserving heart function, enhancing myocardial autophagy in pressure-overloaded hearts and angiotensin II-stimulated cardiomyocytes (Xu M. et al., 2019). In the respect of inhibition for vascular inflammation, oridonin could reduce the endothelial-leukocyte adhesion and leukocyte transmigration, inhibit the expression of TNF-α-induced endothelial adhesion molecules, suppress the penetration of the leukocyte, suppress the TNF-α-activated MAPK and Nuclear factor kappa B (NF-κB) activation, as described in the literature (Huang et al., 2018).

Lung Protective Activity

In recent years, oridonin, isolated from the plants of the genus rubescens, has shown great potential in lung protection due to its antioxidant and anti-inflammatory effects. Oxidative stress and the resulting inflammation are significant pathological processes in acute lung injury (ALI). According to the literature, oridonin can exert protective effects on LPS-induced ALI through Nrf2-independent anti-inflammatory and Nrf2-dependent anti-oxidative activities (Yang et al., 2019b). It also protects against chemical induced pulmonary fibrosis. Research shows that it could markedly suppress the mRNA and protein expression of α-SMA and COL1A1 in TGF-b1-induced MRC-5 cells as well as undermine pathological changes, such as alveolar space collapse, emphysema, and infiltration of inflammatory cells induced by BLM (Fu et al., 2018). Immune regulation disorder and persistent inflammatory injury are important mechanisms of ventilator-induced lung injury (VILI). As research has shown, oridonin can reduce VILI by blocking the interaction between NEK7 and NLRP3 and halting the activation of NLRP3 inflammatory bodies (Liu H. et al., 2020). In addition, post-exposure treatment with oridonin was able to ameliorate lung pathology, attenuate lung edema, abate MDA and TNF-α, and elevate GSH and IL-10 in the lung, which indicate that it can defend the lung against hyperoxia-induced injury in the model of mice (Liu et al., 2017).

Neuroprotective Activity

Oridonin produced a conspicuous effect of neuroprotective in PC12 and N2a cells by rescuing IR, reducing the autophagosome formation and synaptic loss and ameliorating cognitive dysfunction, halting IR-induced synaptic deficits (Wen et al., 2020). In the Aβ_1–42-induced mouse model of Alzheimer’s disease (AD), oridonin sharply rescues synaptic loss induced by Aβ_1–42, lessens the alterations in dendritic structure and spine density, augment PSD-95 and promotes mitochondrial activity (Wang J. et al., 2016). The neuropathological characteristics of AD are amyloid aggregation, tau phosphorylation, and neuroinflammation. A study indicates that different routes of administration of oridonin severely attenuated-amyloid deposition, plaque-associated APP expression and microglial activation, which suggest that this natural terpenoid might be considered a prospective therapeutic agent for human neurodegenerative diseases such as AD (Zhang et al., 2013). Furthermore, available data suggest the potentiality of oridonin to attenuate Aβ_1–42-induced neuroinflammation and inhibit NF-κB pathway (Wang et al., 2014).

Other Pharmacological Activities

Several lines of evidence suggest oridonin exerts its potential role of amelioration lupus-like symptoms through suppressing BAFF expression, improving serological and clinical manifestations of SLE, lessening proteinuria levels, diminishing production of specific auto-antibodies (Zhou et al., 2013). Besides, oridonin exerted its protective effects against hydrogen peroxide-induced damage by altering the profiles of mRNA in human dermal fibroblasts (Lee et al., 2013). In the treatment of respiratory diseases, oridonin could lessen protein quantification in bronchoalveolar lavage fluid and the lung W/D ratio, mitigate inflammation and suppress the injuries, as well as abate the TNF-α, IL-6 (Jiang et al., 2017). Oridonin could also decrease the OVA-induced airway hyper-responsiveness and eosinophil number, and suppress the eosinophilia and mucus production, which confirms its great prospect in the treatment of asthma (Wang S. et al., 2016). In addition, oridonin could effectively ameliorate inflammation-induced bone loss in the model of mice by inhibiting DC-STAMP expression (Zou et al., 2020), halt the growth of methicillin-resistant Staphylococcus aureus (MRSA) (Yuan et al., 2019), mitigate visceral hyperalgesia in a rat model of postinflammatory irritable bowel syndrome (Zang et al., 2016), and augment gamma-globin expression in erythroid precursors from patients (Guo et al., 2020).

Due to the extensive biological effects of oridonin, its application in aquaculture has been gradually discovered in recent years. As reported in the literature, oridonin could improve the antioxidant capacity of arbor acres broilers liver, as evidenced by the decrease in MDA and the increase in total SOD activities and mRNA expression levels of the liver antioxidant genes (Zheng, et al., 2016). Adding oridonin to the diet of arbor acres broilers could significantly improve the immune response induced by Salmonella and protect the intestinal health (Wu et al., 2018a), increase the relative weights of spleen and bursa, number of proliferation peripheral blood T and B lymphocytes, the phagocytic rate of neutrophils, as well as the IL-2, IL-4, and TNF-α (Wu et al., 2018a). In addition, oridonin could also interfere with the effects of Salmonella pullorum on immune cells and Th1/Th2 balance of spleen in arbor acres broilers (Wu et al., 2018b). As discussed above, oridonin is a natural active compound with therapeutic potential for dozens of diseases. Additional details on the pharmacological activities of oridonin were depicted as in Table 1.

Pharmacokinetics

In the process of innovative agent development, pharmacokinetic research has become a pivotal part of preclinical and clinical research of drugs. It not only plays a supporting role in drug toxicity or clinical research, but also contributes to optimize the screening of candidate agents, which provides a novel approach to study modern pharmacotherapy (Sun et al., 2020a). Up to now, benefited from the continuous emergence of novel analytical techniques, researchers have investigated the pharmacokinetic parameters of oridonin in vivo by means of MS-MS (Jin et al., 2010), LC-MS-MS (Du et al., 2010; Jin et al., 2015) and other analytical methods with rats (Jian et al., 2007) and rabbits (Mei et al., 2008), which partially interpreted the kinds of events related to the efficacy and toxicity of relevant herbal preparations in which this constituent is used. Following rat oral administration of Herba Isodi Rubescentis extract containing oridonin (1.68 mg/kg), the pharmacokinetic parameters in rat plasma were obtained with the method of LC-MS-MS, revealing AUC0-t at 78.45 ± 33.83 ng/ml/h and AUC_(0-infinity) at 79.29 ± 34.26 ng/ml/h, t_1/2 at 0.19 ± 0.05 h, T_max at 0.69 ± 0.13 h, C_max at 164.51 ± 58.42 ng/ml (Ma et al., 2013). Determination of oridonin (40 mg/kg) in rat plasma after intragastrical administration with determination of LC-MS-MS suggested that it mainly metabolized in liver, and acquired main pharmacokinetic parameters, such as t_1/2 at 10.88 ± 4.38 h, T_max at 1.00 ± 0.12 h, C_max at 146.9 ± 10.17 ng/ml, AUC(0–t) at 1.31 ± 0.29 mg h/L. At the same time, this project also told us that verapamil could substantially alter the pharmacokinetic profile of oridonin in rats, as well as it might exert these effects via elevating the absorption of this terpenoid compound by suppressing the activity of P-gp, or through hindering the metabolism of it in rat liver (Liu et al., 2019). Figure 3 shows the main metabolites of oridonin.

FIGURE 3

A strategy of using ultra-high-performance liquid chromatography-Triple/time-of-flight mass spectrometry (UPLC-Triple-TOF-MS/MS) to identify metabolites and evaluate the in vitro metabolic profile of oridonin corroborate that, oridonin is universally metabolized in vitro, which the metabolic pathway mainly consists of dehydration, hydroxylation, di-hydroxylation, hydrogenation, decarboxylation, and ketone formation. Meanwhile, 16 metabolites of I- and II-phase were identified (Ma Y. et al., 2016). Another similar study also indicated that 16 phase I and 2 phase II metabolites were detected after oral administration of oridonin in rats, and the main biotransformation pathways of oridonin were reduction, oxidation, dehydroxylation and glucuronic acid coupling (Tian et al., 2015). In addition, the treatment of HepaRG cells with oridonin at concentration of 1, 5, 10, and 20 µM demonstrated that oridonin induced the mRNA and protein expression and enzyme activity of CYP450s, especially on the CYP3A4 and CYP2C9 (Zhang Y. W. et al., 2018). Besides, studies have also shown that oridonin could induce the expression of human CYP3A4 mRNA and protein through pregnane X receptor-mediated (PXR) pathway. Notably, there is no effect on the expression of PXR-nnRNA and protein (Zhang Y.-w. et al., 2014). In the aspect of interaction between oridonin and blood protein, it could bind to human serum albumin (HAS) through hydrogen bonding and van der Waals force, and induce conformational changes of HSA, thus affecting its biological function as carrier protein. The research provides an accurate and full basic data for clarifying the binding mechanism of oridonin with HSA and is beneficial for comprehending its activity on protein function and biological activity in vivo during blood transportation process (Li et al., 2015). Other pharmacokinetic studies on oridonin are shown in Table 2.

Toxicity

When evaluating the efficacy of ingredients, the toxicity and safety of them should be considered particularly (Sun et al., 2020b). For a long time, traditional Chinese medicine (TCM) is well known for its safety. But in recent years, the adverse reactions have been reported frequently. Being a diterpenoids compound broadly distributed in medicinal plants, oridonin has an extensive range of pharmacological activities. However, several lines of evidence indicated that oridonin may exhibit adverse effects, even toxicity under specific circumstances, which sparked intense debate and concern about security of oridonin. As discussed above, it was discovered that oridonin showed antitumor activity on small cell lung cancer (SCLC), but at the same time, HE staining revealed a certain degree of cytotoxicity in hepatic tissue after treatment with oridonin (10 mg/kg) (Xu et al., 2020). In addition, intervention of oridonin induced abnormalities in zebrafish, such as uninflated swim bladder and pericardial congestion at an EC₅₀ of 411.94 mg/L in vitro, as well as it also decreased the body length of zebrafish. In this article, researcher relied on the fact that the downregulation of VEGFR3 gene expression probably be related to the occurrence of abnormalities following oridonin exposure during embryonic development (Tian et al., 2019). A 48 h exposure to oridonin (⩾25 µM) sharply augmented cytosolic Ca2⁺ concentration, potentiated formation of ceramide, and then triggered suicidal death of erythrocytes (Jilani et al., 2011).

On the other hand, some reports suggested that oridonin could induce the expression and activation of CYP2C and CYP3A family (Zhang Y. W. et al., 2018), and appeared to be a potential risk to herb-drug interactions as a result of its induction effects on drug processing genes expression and activation (Zhang Y.-w. et al., 2014). Therefore, these reports suggested that we should pay attention to the safety issues caused by the combination of oridonin in clinical practice. Generally speaking, there are few adverse reports on the safety of oridonin, but the lack of reports does not mean that there are no such potential risks. In view of this, it is particularly important to explore the mechanisms responsible for the adverse risk of oridonin under particular circumstances. Other toxicity researches of oridonin are shown in Table 3.

Summary and Outlooks

Oridonin exists in considerable number of traditional herbal medicines and possesses salient medicinal value. Numerous researches have exhibited that it can regulate a variety of gene and protein expression such as ALP, IL-6, TNF-α, Bcl-2, caspase-3, PGE2, etc. It also shows extensive effects in the regulation of NF-κB, PI3K/Akt/mTOR, and ERK1/2 signaling pathways. This review summarized the mechanism by which oridonin is utilized to treat related diseases (as shown in Table 1) and the related parameters of the pharmacokinetics (as shown in Table 2), as well as security problems in clinical practice (as shown in Table 3). However, there are some issues that need further clarification in future research.

Although oridonin has been proved to possess assorted pharmacological activities in vivo and in vitro, the specific mechanism of its biological activity has not been fully expounded. Hence, it is severely significant to further excavate the mechanism of pharmacological activity at molecular level.

Additionally, as described herein, it has shown prominent adverse effects, even toxicity under specific circumstances in vitro and in vivo. Hence, the conduction of essential investigations and comprehensive strategies to strike the balance between toxicological safety and therapeutic efficacy, as well as the establishment of an all-round research on the effect of dosage on pharmacological activity and toxicity, is highly demanded in this field.

As described herein, oridonin has shown prominent adverse effects, even toxicity under specific circumstances in vitro and in vivo. It showed hepatotoxicity and hepatoprotective effects, which the pair of pharmacological activities seems to be a paradox. However, through the analysis, it is found that this is mainly related to the concentration of oridonin and the time of administration. Long-term administration and high dose administration may cause liver damage. Therefore, it is necessary to further investigate the effects of the concentration of oridonin on pharmacological effects and toxicity. On the other hand, according to the chemical structure of oridonin, it may react covalently with the sulfhydryl group of some proteins, which can partly explain the reason of adverse reactions even toxicity of oridonin in specific environment. In addition, based on the analysis of the existing literatures, we think that the current researches are focus more on the toxicity of oridonin itself. Nevertheless, the toxic process of oridonin metabolites is still unknown. These aspects can be further interpreted in future. Therefore, in view of the above reasons for the safety of oridonin, we suggest that the conduction of essential investigations and comprehensive strategies to strike the balance between toxicological safety and therapeutic efficacy are necessary, as well as the establishment of an all-round research on the effect of dosage on pharmacological activity and toxicity, is highly demanded in this field.

In recent years, structural modification of oridonin, including 1) the derivatization of hydroxyl groups, 2) modification of A-ring, 3) modification of the enone system, and 4) the transformation and derivatization of the framework structure, has been conducted in order to ameliorate the activity and amplify their application scope (Zhang et al., 2020). In the past decades, great progress has been made in structure activity relationship and mechanism of action studies of oridonin for the treatment of malignant tumor and other diseases (Figure 4). The structure and activity relation studies based on these new derivatives have tremendously contributed to the comprehension of their mechanism of actions and molecular targets.

FIGURE 4

According to the above literatures, we deeply realized that an increasing number of reports indicate that oridonin has miscellaneous positive pharmacological activities. However, on the whole, the oridonin’s specific mechanism related various diseases still remain to be clarified. On the other hand, although this natural active ingredient can positively influence the disease process by regulating multiple signal pathways or targets, it is only utilized as adjuvant agents in clinical practice, and rarely applied in the treatment of specific diseases. Therefore, in consideration of the current scattered research, detailed mechanism of oridonin in the treatment of specific diseases should be systematically integrated in the future.

References

• 1

  BaeS.LeeE.-J.LeeJ. H.ParkI.-C.LeeS.-J.HahnH. J.et al (2014). Oridonin Protects Hacat Keratinocytes against Hydrogen Peroxide-Induced Oxidative Stress by Altering Microrna Expression. Int. J. Mol. Med.33, 185–193. 10.3892/ijmm.2013.1561

  • CrossRef
  • Google Scholar

• 2

  BiE.LiuD.LiY.MaoX.WangA.WangJ. (2018). Oridonin Induces Growth Inhibition and Apoptosis in Human Gastric Carcinoma Cells by Enhancement of P53 Expression and Function. Braz. J. Med. Biol. Res.51, e7599. 10.1590/1414-431X20187599

  • CrossRef
  • Google Scholar

• 3

  BohanonF. J.WangX.DingC.DingY.RadhakrishnanG. L.RastelliniC.et al (2014). Oridonin Inhibits Hepatic Stellate Cell Proliferation and Fibrogenesis. J. Surg. Res.190, 55–63. 10.1016/j.jss.2014.03.036

  • CrossRef
  • Google Scholar

• 4

  Bu H.-Q.H.-Q.ShenF.CuiJ. (2019). The Inhibitory Effect of Oridonin on colon Cancer Was Mediated by Deactivation of TGF-β1/Smads-PAI-1 Signaling Pathway In Vitro and Vivo. Onco Targets Ther.12, 7467–7476. 10.2147/Ott.S220401

  • CrossRef
  • Google Scholar

• 5

  Bu H.H.LiuD.CuiJ.CaiK.ShenF. (2019). Wnt/β-catenin Signaling Pathway Is Involved in Induction of Apoptosis by Oridonin in colon Cancer COLO205 Cells. Transl. Cancer Res.8, 1782–1794. 10.21037/tcr.2019.08.25

  • CrossRef
  • Google Scholar

• 6

  CaoS.HuangY.ZhangQ.LuF.DonkorP. O.ZhuY.et al (2019). Molecular Mechanisms of Apoptosis and Autophagy Elicited by Combined Treatment with Oridonin and Cetuximab in Laryngeal Squamous Cell Carcinoma. Apoptosis24, 33–45. 10.1007/s10495-018-1497-0

  • CrossRef
  • Google Scholar

• 7

  ChenK.YeJ.QiL.LiaoY.LiR.SongS.et al (2019). Oridonin Inhibits Hypoxia-Induced Epithelial-Mesenchymal Transition and Cell Migration by the Hypoxia-Inducible Factor-1α/matrix Metallopeptidase-9 Signal Pathway in Gallbladder Cancer. Anti-Cancer Drug30, 925–932. 10.1097/Cad.0000000000000797

  • CrossRef
  • Google Scholar

• 8

  ChengW.HuangC.MaW.TianX.ZhangX. (2018). Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities. Mini Rev Med Chem.19, 114–124. 10.2174/1389557517666170417170609

  • CrossRef
  • Google Scholar

• 9

  ClaytonJ. E.HeldP. G.LarsonB.BanksP. (2016). Quantification of Oridonin-Induced Apoptosis and Cytotoxicity in Cancer Cells Using Noninvasive Live-Cell Imaging. Mol. Biol. Cel27, P1088.

  • Google Scholar

• 10

  CumminsC. B.WangX.SommerhalderC.BohanonF. J.Nunez LopezO.TieH.-Y.et al (2018). Natural Compound Oridonin Inhibits Endotoxin-Induced Inflammatory Response of Activated Hepatic Stellate Cells. Biomed. Res. Int.2018, 1–10. 10.1155/2018/6137420

  • CrossRef
  • Google Scholar

• 11

  CumminsC.WangX.GuY.FangX.RadhakrishnanR. (2019). Protective Effects of Oridonin on Intestinal Epithelial Cells by Suppressing TNFα-Induced Inflammation and Epithelial-Mesenchymal Transition. J. Am. Coll. Surgeons229, e239–e240. 10.1016/j.jamcollsurg.2019.08.1390

  • CrossRef
  • Google Scholar

• 12

  DengY.ChenC.YuH.DiaoH.ShiC.WangY.et al (2017). Oridonin Ameliorates Lipopolysaccharide/d-Galactosamine-Induced Acute Liver Injury in Mice via Inhibition of Apoptosis. Am. J. Transl Res.9, 4271–4279.

  • Google Scholar

• 13

  DongX.LiuF.LiM. (2016). Inhibition of Nuclear Factor κB Transcription Activity Drives a Synergistic Effect of Cisplatin and Oridonin on HepG2 Human Hepatocellular Carcinoma Cells. Anti-Cancer Drug27, 286–299. 10.1097/Cad.0000000000000329

  • CrossRef
  • Google Scholar

• 14

  DongY. L.HuangC. P.LiJ. (2018). The Inhibitive Effects of Oridonin on Cisplatin-Resistant Ovarian Cancer Cells via Inducing Cell Apoptosis and Inhibiting Adam17. Acta Med. Mediterr34, 819–825. 10.19193/0393-6384_2018_3_125

  • CrossRef
  • Google Scholar

• 15

  DuY.LiuP.ShiX.JinY.WangQ.ZhangX.et al (2010). A Novel Analysis Method for Diterpenoids in Rat Plasma by Liquid Chromatography-Electrospray Ionization Mass Spectrometry. Anal. Biochem.407, 111–119. 10.1016/j.ab.2010.07.009

  • CrossRef
  • Google Scholar

• 16

  FuY.ZhaoP.XieZ.WangL.ChenS. (2018). Oridonin Inhibits Myofibroblast Differentiation and Bleomycin-Induced Pulmonary Fibrosis by Regulating Transforming Growth Factor β (TGFβ)/Smad Pathway. Med. Sci. Monit.24, 7548–7555. 10.12659/Msm.912740

  • CrossRef
  • Google Scholar

• 17

  GaoS.TanH.ZhuN.GaoH.LvC.GangJ.et al (2016). Oridonin Induces Apoptosis through the Mitochondrial Pathway in Human Gastric Cancer Sgc-7901 Cells. Int. J. Oncol.48, 2453–2460. 10.3892/ijo.2016.3479

  • CrossRef
  • Google Scholar

• 18

  GongL.XuH.ZhangX.ZhangT.ShiJ.ChangH. (2019). Oridonin Relieves Hypoxia-Evoked Apoptosis and Autophagy via Modulating Microrna-214 in H9c2 Cells. Artif. Cell Nanomedicine, Biotechnol.47, 2585–2592. 10.1080/21691401.2019.1628037

  • CrossRef
  • Google Scholar

• 19

  GuZ.WangX.QiR.WeiL.HuoY.MaY.et al (2015). Oridonin Induces Apoptosis in Uveal Melanoma Cells by Upregulation of Bim and Downregulation of Fatty Acid Synthase. Biochem. Biophysical Res. Commun.457, 187–193. 10.1016/j.bbrc.2014.12.086

  • CrossRef
  • Google Scholar

• 20

  GuiZ.LiS.LiuX.XuB.XuJ. (2015). Oridonin Alters the Expression Profiles of Micrornas in Bxpc-3 Human Pancreatic Cancer Cells. BMC Complement. Altern. Med.15, 117. 10.1186/s12906-015-0640-5

  • CrossRef
  • Google Scholar

• 21

  GuiZ.LuoF.YangY.ShenC.LiS.XuJ. (2017). Oridonin Inhibition and Mir-200b-3p/zeb1 axis in Human Pancreatic Cancer. Int. J. Oncol.50, 111–120. 10.3892/ijo.2016.3772

  • CrossRef
  • Google Scholar

• 22

  GuoL.ChenJ.WangQ.ZhangJ.HuangW. (2020). Oridonin Enhances γ-globin Expression in Erythroid Precursors from Patients with β-thalassemia via Activation of P38 MAPK Signaling. Mol. Med. Rep.21, 909–917. 10.3892/mmr.2019.10848

  • CrossRef
  • Google Scholar

• 23

  GuoW.ZhengP.ZhangJ.MingL.ZhouC.ZhangS. (2013). Oridonin Suppresses Transplant Rejection by Depleting T Cells from the Periphery. Int. Immunopharmacology17, 1148–1154. 10.1016/j.intimp.2013.10.023

  • CrossRef
  • Google Scholar

• 24

  HanJ. M.HongK. O.YangI. H.AhnC. H.JinB.LeeW.et al (2020). Oridonin Induces the Apoptosis of Mucoepidermoid Carcinoma Cell Lines in a Myeloid Cell Leukemia-1-dependent Manner. Int. J. Oncol.57, 377–385. 10.3892/ijo.2020.5061

  • CrossRef
  • Google Scholar

• 25

  HaoY.LiJ.LuoY. Y.ZhangM.LiS. S. (2016). Proteomic Research on Honeybee. J. Tradit Chin. Med.36, 225–252. 10.1007/978-3-319-43275-5_12

  • CrossRef
  • Google Scholar

• 26

  HeH. B.JiangH.ChenY.DengX.JiangW.ZhouR. (2019). Oridonin Is a Covalent Nlrp3 Inhibitor with strong Anti-inflammasome Activity. Eur. J. Immunol.49, 192.

  • Google Scholar

• 27

  HeS.-D.HuangS.-G.ZhuH.-J.LuoX.-G.LiaoK.-H.ZhangJ.-Y.et al (2020). Oridonin Suppresses Autophagy and Survival in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Pharm. Biol.58, 146–151. 10.1080/13880209.2020.1711783

  • CrossRef
  • Google Scholar

• 28

  HeZ.XiaoX.LiS.GuoY.HuangQ.ShiX.et al (2017). Oridonin Induces Apoptosis and Reverses Drug Resistance in Cisplatin Resistant Human Gastric Cancer Cells. Oncol. Lett.14, 2499–2504. 10.3892/ol.2017.6421

  • CrossRef
  • Google Scholar

• 29

  HuX.WangY.GaoX.XuS.ZangL.XiaoY.et al (2020). Recent Progress of Oridonin and its Derivatives for the Treatment of Acute Myelogenous Leukemia. Mini Rev Med Chem20, 483–497. 10.2174/1389557519666191029121809

  • CrossRef
  • Google Scholar

• 30

  HuangJ.-H.LanC.-C.HsuY.-T.TsaiC.-L.TzengI.-S.WangP.et al (2020). Oridonin Attenuates Lipopolysaccharide-Induced Ros Accumulation and Inflammation in Hk-2 Cells. Evidence-Based Complement. Altern. Med.2020, 1–8. 10.1155/2020/9724520

  • CrossRef
  • Google Scholar

• 31

  HuangW.HuangM.OuyangH.PengJ.LiangJ. (2018). Oridonin Inhibits Vascular Inflammation by Blocking NF-κB and MAPK Activation. Eur. J. Pharmacol.826, 133–139. 10.1016/j.ejphar.2018.02.044

  • CrossRef
  • Google Scholar

• 32

  JeonM.-Y.SeoS. U.WooS. M.MinK.-j.ByunH. S.HurG. M.et al (2019). Oridonin Enhances Trail-Induced Apoptosis through Galnt14-Mediated Dr5 Glycosylation. Biochimie165, 108–114. 10.1016/j.biochi.2019.07.015

  • CrossRef
  • Google Scholar

• 33

  JiaT.CaiM.MaX.LiM.QiaoJ.ChenT. (2019). Oridonin Inhibits IL-1β-induced Inflammation in Human Osteoarthritis Chondrocytes by Activating PPAR-γ. Int. Immunopharmacology69, 382–388. 10.1016/j.intimp.2019.01.049

  • CrossRef
  • Google Scholar

• 34

  JianG.WangY.-W.LuX.-C.CaoJ.-Y. (2007). Determination of Oridonin in Rat Plasma by Reverse-phase High-Performance Liquid Chromatography. J. Pharm. Biomed. Anal.43, 793–797. 10.1016/j.prp.2020.153031

  • CrossRef
  • Google Scholar

• 35

  JianZ. Y.XuG. F.DaiL. (2019). Analysis on the Accumulation of Oridonin in Different Portions of Isodon Rubescens (Hemsley) H. Hara. Bangladesh J. Bot.48, 1193–1197. 10.3329/bjb.v48i4.49075

  • CrossRef
  • Google Scholar

• 36

  JiangJ.-H.PiJ.CaiJ.-Y. (2020). Oridonin Exhibits Anti-angiogenic Activity in Human Umbilical Vein Endothelial Cells by Inhibiting Vegf-Induced Vegfr-2 Signaling Pathway. Pathol. - Res. Pract.216, 153031. 10.1016/j.prp.2020.153031

  • CrossRef
  • Google Scholar

• 37

  JiangJ. H.PiJ.JinH.CaiJ. Y. (2019). Oridonin‐induced Mitochondria‐dependent Apoptosis in Esophageal Cancer Cells by Inhibiting PI3K/AKT/mTOR and Ras/Raf Pathways. J. Cel Biochem120, 3736–3746. 10.1002/jcb.27654

  • CrossRef
  • Google Scholar

• 38

  JiangJ.ShanX. X.ZhuL. (2017). Effects and Mechanisms of Oridonin in the Treatment of Acute Respiratory Distress Syndrome Mice. Int. J. Clin. Exp. Med.10, 6191–6197.

  • Google Scholar

• 39

  JilaniK.QadriS. M.ZelenakC.LangF. (2011). Stimulation of Suicidal Erythrocyte Death by Oridonin. Arch. Biochem. Biophys.511, 14–20. 10.1016/j.abb.2011.05.001

  • CrossRef
  • Google Scholar

• 40

  JinY.DuY.ShiX.LiuP. (2010). Simultaneous Quantification of 19 Diterpenoids in Isodon Amethystoides by High-Performance Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry. J. Pharm. Biomed. Anal.53, 403–411. 10.1016/j.jpba.2010.04.030

  • CrossRef
  • Google Scholar

• 41

  JinY.TianT.MaY.XuH.DuY. (2015). Simultaneous Determination of Ginsenoside Rb1, Naringin, Ginsenoside Rb2 and Oridonin in Rat Plasma by LC-MS/MS and its Application to a Pharmacokinetic Study after Oral Administration of Weifuchun Tablet. J. Chromatogr. B1000, 112–119. 10.1016/j.jchromb.2015.06.027

  • CrossRef
  • Google Scholar

• 42

  KadiogluO.SaeedM.KueteV.GretenH. J.EfferthT. (2018). Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by In Silico and In Vitro Analyses. Front. Pharmacol.9, 355. 10.3389/fphar.2018.00355

  • CrossRef
  • Google Scholar

• 43

  KangN.CaoS.-J.ZhouY.HeH.TashiroS.-I.OnoderaS.et al (2015). Inhibition of Caspase-9 by Oridonin, a Diterpenoid Isolated from Rabdosia Rubescens, Augments Apoptosis in Human Laryngeal Cancer Cells. Int. J. Oncol.47, 2045–2056. 10.3892/ijo.2015.3186

  • CrossRef
  • Google Scholar

• 44

  KangN.CaoS.JiangB.ZhangQ.DonkorP. O.ZhuY.et al (2020). Cetuximab Enhances Oridonin-Induced Apoptosis through Mitochondrial Pathway and Endoplasmic Reticulum Stress in Laryngeal Squamous Cell Carcinoma Cells. Toxicol. Vitro67, 104885. 10.1016/j.tiv.2020.104885

  • CrossRef
  • Google Scholar

• 45

  LeeE.-J.ChaH. J.AhnK. J.AnI.-S.AnS.BaeS. (2013). Oridonin Exerts Protective Effects against Hydrogen Peroxide-Induced Damage by Altering Microrna Expression Profiles in Human Dermal Fibroblasts. Int. J. Mol. Med.32, 1345–1354. 10.3892/ijmm.2013.1533

  • CrossRef
  • Google Scholar

• 46

  LiC.WangQ.ShenS.WeiX.LiG. (2018). Oridonin Inhibits VEGF-A-associated Angiogenesis and Epithelial-mesenchymal Transition of Breast Cancer In Vitro and In Vivo. Oncol. Lett.16, 2289–2298. 10.3892/ol.2018.8943

  • CrossRef
  • Google Scholar

• 47

  LiC. Y.WangQ.ShenS.WeiX. L.LiG. X. (2018). Oridonin Inhibits Migration, Invasion, Adhesion and TGF-β1-induced Epithelial-mesenchymal Transition of Melanoma Cells by Inhibiting the Activity of PI3K/Akt/GSK-3β Signaling Pathway. Oncol. Lett.15, 1362–1372. 10.3892/ol.2017.7421

  • CrossRef
  • Google Scholar

• 48

  LiD.HanT.XuS.ZhouT.TianK.HuX.et al (2016). Antitumor and Antibacterial Derivatives of Oridonin: A Main Composition of Dong-Ling-Cao. Molecules21, 575. 10.3390/molecules21050575

  • CrossRef
  • Google Scholar

• 49

  LiJ.BaoL.ZhaD.ZhangL.GaoP.ZhangJ.et al (2018). Oridonin Protects against the Inflammatory Response in Diabetic Nephropathy by Inhibiting the TLR4/p38-MAPK and TLR4/NF-κB Signaling Pathways. Int. Immunopharmacology55, 9–19. 10.1016/j.intimp.2017.11.040

  • CrossRef
  • Google Scholar

• 50

  LiJ.WuY.WangD.ZouL.FuC.ZhangJ.et al (2019). Oridonin Synergistically Enhances the Anti-tumor Efficacy of Doxorubicin against Aggressive Breast Cancer via Pro-apoptotic and Anti-angiogenic Effects. Pharmacol. Res.146, 104313. 10.1016/j.phrs.2019.104313

  • CrossRef
  • Google Scholar

• 51

  LiS.ShiD.ZhangL.YangF.ChengG. (2018). Oridonin Enhances the Radiosensitivity of Lung Cancer Cells by Upregulating Bax and Downregulating Bcl-2. Exp. Ther. Med.16, 4859–4864. 10.3892/etm.2018.6803

  • CrossRef
  • Google Scholar

• 52

  LiW.MaL. (2019). Synergistic Antitumor Activity of Oridonin and Valproic Acid on HL‐60 Leukemia Cells. J. Cel Biochem120, 5620–5627. 10.1002/jcb.27845

  • CrossRef
  • Google Scholar

• 53

  LiX.YangZ. (2015). Interaction of Oridonin with Human Serum Albumin by Isothermal Titration Calorimetry and Spectroscopic Techniques. Chemico-Biological Interactions232, 77–84. 10.1016/j.cbi.2015.03.012

  • CrossRef
  • Google Scholar

• 54

  LiY.-C.SunM.-R.ZhaoY.-H.FuX.-Z.XuH.-W.LiuJ.-F. (2016). Oridonin Suppress Cell Migration via Regulation of Nonmuscle Myosin Iia. Cytotechnology68, 389–397. 10.1007/s10616-014-9790-4

  • CrossRef
  • Google Scholar

• 55

  LiY.WangY.WangS.GaoY.ZhangX.LuC. H.et al (2015). Oridonin Phosphate-Induced Autophagy Effectively Enhances Cell Apoptosis of Human Breast Cancer Cells. Med. Oncol.32, 365. 10.1007/s12032-014-0365-1

  • CrossRef
  • Google Scholar

• 56

  LiangJ.WangW.WeiL.GaoS.WangY. (2018). Oridonin Inhibits Growth and Induces Apoptosis of Human Neurocytoma Cells via the Wnt/β-catenin Pathway. Oncol. Lett.16, 3333–3340. 10.3892/ol.2018.8977

  • CrossRef
  • Google Scholar

• 57

  LiermannJ.NaumannP.FortunatoF.SchmidT. E.WeberK.-J.DebusJ.et al (2017). Phytotherapeutics Oridonin and Ponicidin Show Additive Effects Combined with Irradiation in Pancreatic Cancer In Vitro. Radiol. Oncol.51, 407–414. 10.1515/raon-2017-0048

  • CrossRef
  • Google Scholar

• 58

  LinK.-H.LiC.-Y.HsuY.-M.TsaiC.-H.TsaiF.-J.TangC.-H.et al (2019). Oridonin, A Natural Diterpenoid, Protected NGF-Differentiated PC12 Cells against MPP+- and Kainic Acid-Induced Injury. Food Chem. Toxicol.133, 110765. 10.1016/j.fct.2019.110765

  • CrossRef
  • Google Scholar

• 59

  LiuD.-L.BuH.-Q.JinH.-M.ZhaoJ.-F.LiY.HuangH. (2014). Enhancement of the Effects of Gemcitabine against Pancreatic Cancer by Oridonin via the Mitochondrial Caspase-dependent Signaling Pathway. Mol. Med. Rep.10, 3027–3034. 10.3892/mmr.2014.2584

  • CrossRef
  • Google Scholar

• 60

  LiuD.-L.BuH.-Q.WangW.-L.LuoH.ChengB.-N. (2020). Oridonin Enhances the Anti-tumor Activity of Gemcitabine towards Pancreatic Cancer by Stimulating Bax- and Smac-dependent Apoptosis. Transl Cancer Res. TCR9, 4148–4161. 10.21037/tcr-19-3000

  • CrossRef
  • Google Scholar

• 61

  LiuD.QinH.YangB.DuB.YunX. (2020). Oridonin Ameliorates Carbon Tetrachloride‐induced Liver Fibrosis in Mice through Inhibition of the NLRP3 Inflammasome. Drug Dev. Res.81, 526–533. 10.1002/ddr.21649

  • CrossRef
  • Google Scholar

• 62

  LiuH.GuC.LiuM.LiuG.WangY. (2020). Nek7 Mediated Assembly and Activation of Nlrp3 Inflammasome Downstream of Potassium Efflux in Ventilator-Induced Lung Injury. Biochem. Pharmacol.177, 113998. 10.1016/j.bcp.2020.113998

  • CrossRef
  • Google Scholar

• 63

  LiuJ.ZhangN.LiN.FanX.LiY.LiY. (2019). Influence of Verapamil on the Pharmacokinetics of Oridonin in Rats. Pharm. Biol.57, 787–791. 10.1080/13880209.2019.1688844

  • CrossRef
  • Google Scholar

• 64

  LiuR.-X.MaY.HuX.-L.RenW.-Y.LiaoY.-P.WangH.et al (2018). Anticancer Effects of Oridonin on colon Cancer Are Mediated via Bmp7/p38 Mapk/p53 Signaling. Int. J. Oncol.53, 2091–2101. 10.3892/ijo.2018.4527

  • CrossRef
  • Google Scholar

• 65

  LiuW.HuangG.YangY.GaoR.ZhangS.KouB. (2021). Oridonin Inhibits Epithelial-Mesenchymal Transition of Human Nasopharyngeal Carcinoma Cells by Negatively Regulating Akt/stat3 Signaling Pathway. Int. J. Med. Sci.18, 81–87. 10.7150/ijms.48552

  • CrossRef
  • Google Scholar

• 66

  LiuX.KangJ.WangH.HuangT.HuangT. (2018). Mitochondrial Ros Contribute to Oridonin-Induced Hepg2 Apoptosis through Parp Activation. Oncol. Lett.15, 2881–2888. 10.3892/ol.2017.7665

  • CrossRef
  • Google Scholar

• 67

  LiuY.ZhangP.-x.HanC.-h.WeiD.QiaoT.PengB.et al (2017). Oridonin Protects the Lung against Hyperoxia-Induced Injury in a Mouse Model. Undersea Hyperb Med44, 33–38. 10.22462/1.2.2017.6

  • CrossRef
  • Google Scholar

• 68

  LouS.XuJ.WangB.LiS.RenJ.HuZ.et al (2019). Downregulation of Lncrna Afap1-As1 by Oridonin Inhibits the Epithelial-To-Mesenchymal Transition and Proliferation of Pancreatic Cancer Cells. Acta Bioch Bioph Sin51, 814–825. 10.1093/abbs/gmz071

  • CrossRef
  • Google Scholar

• 69

  LuC.ChenC.ChenA.WuY.WenJ.HuangF.et al (2020). Oridonin Attenuates Myocardial Ischemia/reperfusion Injury via Downregulating Oxidative Stress and Nlrp3 Inflammasome Pathway in Mice. Evidence-Based Complement. Altern. Med.2020, 1–9. 10.1155/2020/7395187

  • CrossRef
  • Google Scholar

• 70

  LuJ.ChenX.QuS.YaoB.XuY.WuJ.et al (2017). Oridonin Induces G2/M Cell Cycle Arrest and Apoptosis via the PI3K/Akt Signaling Pathway in Hormone-independent Prostate Cancer Cells. Oncol. Lett.13, 2838–2846. 10.3892/ol.2017.5751

  • CrossRef
  • Google Scholar

• 71

  MaB.WangY.ZhangQ.LiuY.LiJ.XuQ.et al (2013). Simultaneous Determination of Oridonin, Ponicidin and Rosmarinic Acid from Herba Isodi Rubescentis Extract by Lc-Ms-Ms in Rat Plasma. J. Chromatogr. Sci.51, 910–918. 10.1093/chromsci/bms189

  • CrossRef
  • Google Scholar

• 72

  Ma S.S.TanW.DuB.LiuW.LiW.CheD.et al (2016). Oridonin Effectively Reverses Cisplatin Drug Resistance in Human Ovarian Cancer Cells via Induction of Cell Apoptosis and Inhibition of Matrix Metalloproteinase Expression. Mol. Med. Rep.13, 3342–3348. 10.3892/mmr.2016.4897

  • CrossRef
  • Google Scholar

• 73

  Ma Y.Y.XieW.TianT.JinY.XuH.ZhangK.et al (2016). Identification and Comparative Oridonin Metabolism in Different Species Liver Microsomes by Using Uplc-Triple-Tof-Ms/ms and Pca. Anal. Biochem.511, 61–73. 10.1016/j.ab.2016.08.004

  • CrossRef
  • Google Scholar

• 74

  MeiY.XuJ.ZhaoJ.FengN.LiuY.WeiL. (2008). An Hplc Method for Determination of Oridonin in Rabbits Using Isopsoralen as an Internal Standard and its Application to Pharmacokinetic Studies for Oridonin-Loaded Nanoparticles. J. Chromatogr. B869, 138–141. 10.1016/j.jchromb.2008.05.005

  • CrossRef
  • Google Scholar

• 75

  MengL.GuiX.YunZ. (2019). A New Method to Extract Oridonin and Rosmarinic Acid Simultaneously from Rabdosia Rubescens. Int. J. Food Eng.15, 1–11. 10.1515/ijfe-2019-0013

  • CrossRef
  • Google Scholar

• 76

  OhH.-N.SeoJ.-H.LeeM.-H.YoonG.ChoS.-S.LiuK.et al (2018). Oridonin Induces Apoptosis in Oral Squamous Cell Carcinoma Probably through the Generation of Reactive Oxygen Species and the P38/jnk Mapk Pathway. Int. J. Oncol.52, 1749–1759. 10.3892/ijo.2018.4319

  • CrossRef
  • Google Scholar

• 77

  ParkH.JeongY.HanN.-K.KimJ.LeeH.-J. (2018). Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-small Cell Lung Cancer Cells. Int J Mol Sci.19, 2378. 10.3390/ijms19082378

  • CrossRef
  • Google Scholar

• 78

  PiJ.CaiH.JinH.YangF.JiangJ.WuA.et al (2015). Qualitative and Quantitative Analysis of Ros-Mediated Oridonin-Induced Oesophageal Cancer Kyse-150 Cell Apoptosis by Atomic Force Microscopy. Plos One10, e0140935. 10.1371/journal.pone.0140935

  • CrossRef
  • Google Scholar

• 79

  QingK.JinZ.FuW.WangW.LiuZ.LiX.et al (2016). Synergistic Effect of Oridonin and a Pi3k/mtor Inhibitor on the Non-germinal center B Cell-like Subtype of Diffuse Large B Cell Lymphoma. J. Hematol. Oncol.9, 72. 10.1186/s13045-016-0303-0

  • CrossRef
  • Google Scholar

• 80

  RenC.-M.LiY.ChenQ.-Z.ZengY.-H.ShaoY.WuQ.-X.et al (2016). Oridonin Inhibits the Proliferation of Human colon Cancer Cells by Upregulating Bmp7 to Activate P38 Mapk. Oncol. Rep.35, 2691–2698. 10.3892/or.2016.4654

  • CrossRef
  • Google Scholar

• 81

  RenD. L.GhoorunR.WuX. H.ChenH. L.ZhouQ.WuX. B. (2020). Oridonin Induces Apoptosis in HGC-27 Cells by Activating the JNK Signaling Pathway. Oncol. Lett.19, 255–260. 10.3892/ol.2019.11104

  • CrossRef
  • Google Scholar

• 82

  ShangC.-h.ZhangQ.-q.ZhouJ.-h. (2016). Oridonin Inhibits Cell Proliferation and Induces Apoptosis in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Inflammation39, 873–880. 10.1007/s10753-016-0318-2

  • CrossRef
  • Google Scholar

• 83

  ShiM.DengY.YuH.XuL.ShiC.ChenJ.et al (2019). Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (Irak4) in the Toll-like Receptor 4 (Tlr4) Signaling Pathway. Mediators Inflamm.2019, 1–11. 10.1155/2019/7634761

  • CrossRef
  • Google Scholar

• 84

  ShiM.LuX.-J.ZhangJ.DiaoH.LiG.XuL.et al (2016). Oridonin, a Novel Lysine Acetyltransferases Inhibitor, Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cells through P53- and Caspase-3-Mediated Mechanisms. Oncotarget7, 22623–22631. 10.18632/oncotarget.8033

  • CrossRef
  • Google Scholar

• 85

  SpirinP.LebedevT.OrlovaN.MorozovA.PoymenovaN.DmitrievS. E.et al (2017). Synergistic Suppression of T(8;21)-Positive Leukemia Cell Growth by Combining Oridonin and Mapk1/erk2 Inhibitors. Oncotarget8, 56991–57002. 10.18632/oncotarget.18503

  • CrossRef
  • Google Scholar

• 86

  SunQ.HeM.ZhangM.ZengS.ChenL.ZhouL.et al (2020a). Ursolic Acid: A Systematic Review of its Pharmacology, Toxicity and Rethink on its Pharmacokinetics Based on PK-PD Model. Fitoterapia147, 104735. 10.1016/j.fitote.2020.104735

  • CrossRef
  • Google Scholar

• 87

  SunQ.XieL.SongJ.LiX. (2020b). Evodiamine: A Review of its Pharmacology, Toxicity, Pharmacokinetics and Preparation Researches. J. Ethnopharmacology262, 113164. 10.1016/j.jep.2020.113164

  • CrossRef
  • Google Scholar

• 88

  SunY.JiangX.LuY.ZhuJ.YuL.MaB.et al (2018). Oridonin Prevents Epithelial-Mesenchymal Transition and TGF-β1-Induced Epithelial-Mesenchymal Transition by Inhibiting TGF-β1/Smad2/3 in Osteosarcoma. Chemico-Biological Interactions296, 57–64. 10.1016/j.cbi.2018.09.013

  • CrossRef
  • Google Scholar

• 89

  SunZ.HanQ.DuanL.YuanQ.WangH. (2018). Oridonin Increases Anticancer Effects of Lentinan in Hepg2 Human Hepatoblastoma Cells. Oncol. Lett.15, 1999–2005. 10.3892/ol.2017.7485

  • CrossRef
  • Google Scholar

• 90

  TianL.ShengD.LiQ.GuoC.ZhuG. (2019). Preliminary Safety Assessment of Oridonin in Zebrafish. Pharm. Biol.57, 632–640. 10.1080/13880209.2019.1662457

  • CrossRef
  • Google Scholar

• 91

  TianL.XieK.ShengD.WanX.ZhuG. (2017). Antiangiogenic Effects of Oridonin. BMC Complement. Altern. Med.17, 192. 10.1186/s12906-017-1706-3

  • CrossRef
  • Google Scholar

• 92

  TianT.JinY.MaY.XieW.XuH.ZhangK.et al (2015). Identification of Metabolites of Oridonin in Rats with a Single Run on Uplc-Triple-Tof-Ms/ms System Based on Multiple Mass Defect Filter Data Acquisition and Multiple Data Processing Techniques. J. Chromatogr. B1006, 80–92. 10.1016/j.jchromb.2015.10.006

  • CrossRef
  • Google Scholar

• 93

  TiwariR. V.ParajuliP.SylvesterP. W. (2015). Synergistic Anticancer Effects of Combined γ-tocotrienol and Oridonin Treatment Is Associated with the Induction of Autophagy. Mol. Cel Biochem408, 123–137. 10.1007/s11010-015-2488-x

  • CrossRef
  • Google Scholar

• 94

  VasaturoM.CotugnoR.FiengoL.VinegoniC.Dal PiazF.De TommasiN. (2018). The Anti-tumor Diterpene Oridonin Is a Direct Inhibitor of Nucleolin in Cancer Cells. Sci. Rep.8, 16735. 10.1038/s41598-018-35088-x

  • CrossRef
  • Google Scholar

• 95

  WangB.ShenC.LiY.ZhangT.HuangH.RenJ.et al (2019). Oridonin Overcomes the Gemcitabine Resistant Panc-1/gem Cells by Regulating Gst Pi and Lrp/1 Erk/jnk Signalling. Onco Targets Ther.12, 5751–5765. 10.2147/Ott.S208924

  • CrossRef
  • Google Scholar

• 96

  WangJ.LiF.DingJ.TianG.JiangM.GaoZ.et al (2016). Investigation of the Anti-asthmatic Activity of Oridonin on a Mouse Model of Asthma. Mol. Med. Rep.14, 2000–2006. 10.3892/mmr.2016.5485

  • CrossRef
  • Google Scholar

• 97

  WangS.YangH.YuL.JinJ.QianL.ZhaoH.et al (2014). Oridonin Attenuates Aβ1-42-Induced Neuroinflammation and Inhibits NF-κB Pathway. Plos One9, e104745. 10.1371/journal.pone.0104745

  • CrossRef
  • Google Scholar

• 98

  WangS.YuL.YangH.LiC.HuiZ.XuY.et al (2016). Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1-42-Induced Mouse Model of Alzheimer's Disease. Plos One11, e0151397–16. 10.1371/journal.pone.0151397

  • CrossRef
  • Google Scholar

• 99

  WangS.ZhangY.SaasP.WangH.XuY.ChenK.et al (2015). Oridonin's Therapeutic Effect: Suppressing Th1/Th17 Simultaneously in a Mouse Model of Crohn's Disease. J. Gastroenterol. Hepatol.30, 504–512. 10.1111/jgh.12710

  • CrossRef
  • Google Scholar

• 100

  WangY.ZhuZ. (2019). Oridonin Inhibits Metastasis of Human Ovarian Cancer Cells by Suppressing the Mtor Pathway. aoms15, 1017–1027. 10.5114/aoms.2018.77068

  • CrossRef
  • Google Scholar

• 101

  WenF.ZhugeW.WangJ.LuX.YouR.LiuL.et al (2020). Oridonin Prevents Insulin Resistance-Mediated Cognitive Disorder through Pten/akt Pathway and Autophagy in Minimal Hepatic Encephalopathy. J. Cel Mol Med24, 61–78. 10.1111/jcmm.14546

  • CrossRef
  • Google Scholar

• 102

  WuH.ZhuG. H.SuY. Z. (2020). Oridonin Improves the Sensitivity of Multiple Myeloma Cells to Bortezomib through the Pten/pi3k/akt Pathway. Curr. Top. Nutraceut R.18, 292–296. 10.37290/ctnr2641-452X.18:292-296

  • CrossRef
  • Google Scholar

• 103

  WuQ.-X.YuanS.-X.RenC.-M.YuY.SunW.-J.HeB.-C.et al (2016). Oridonin Upregulates Pten through Activating P38 Mapk and Inhibits Proliferation in Human colon Cancer Cells. Oncol. Rep.35, 3341–3348. 10.3892/or.2016.4735

  • CrossRef
  • Google Scholar

• 104

  WuQ. J.ZhengX. C.WangT.ZhangT. Y. (2018a). Effect of Dietary Oridonin Supplementation on Growth Performance, Gut Health, and Immune Response of Broilers Infected with salmonella Pullorum. Ir Vet. J.71, 1–6. 10.1186/s13620-018-0128-y

  • CrossRef
  • Google Scholar

• 105

  WuQ. J.ZhengX. C.WangT.ZhangT. Y. (2018b). Effects of Dietary Supplementation with Oridonin on the Growth Performance, Relative Organ Weight, Lymphocyte Proliferation, and Cytokine Concentration in Broiler Chickens. Bmc Vet. Res.14, 34. 10.1186/s12917-018-1359-6

  • CrossRef
  • Google Scholar

• 106

  WuQ. J.ZhengX. C.WangT.ZhangT. Y. (2018c). Effects of Oridonin on Immune Cells, Th1/th2 Balance and the Expression of Blys in the Spleens of Broiler Chickens Challenged with salmonella Pullorum. Res. Vet. Sci.119, 262–267. 10.1016/j.rvsc.2018.07.008

  • CrossRef
  • Google Scholar

• 107

  XiaS.ZhangX.LiC.GuanH. (2017). Oridonin Inhibits Breast Cancer Growth and Metastasis through Blocking the Notch Signaling. Saudi Pharm. J.25, 638–643. 10.1016/j.jsps.2017.04.037

  • CrossRef
  • Google Scholar

• 108

  XiaoX.HeZ.CaoW.CaiF.ZhangL.HuangQ.et al (2016). Oridonin Inhibits Gefitinib-Resistant Lung Cancer Cells by Suppressing Egfr/erk/mmp-12 and Cip2a/akt Signaling Pathways. Int. J. Oncol.48, 2608–2618. 10.3892/ijo.2016.3488

  • CrossRef
  • Google Scholar

• 109

  XuL.BiY.XuY.ZhangZ.XuW.ZhangS.et al (2020). Oridonin Inhibits the Migration and Epithelial‐to‐mesenchymal Transition of Small Cell Lung Cancer Cells by Suppressing FAK‐ERK1/2 Signalling Pathway. J. Cel Mol Med24, 4480–4493. 10.1111/jcmm.15106

  • CrossRef
  • Google Scholar

• 110

  XuL.LiL.ZhangC.-Y.SchluesenerH.ZhangZ.-Y. (2019). Natural Diterpenoid Oridonin Ameliorates Experimental Autoimmune Neuritis by Promoting Anti-inflammatory Macrophages through Blocking Notch Pathway. Front. Neurosci.13, 272. 10.3389/fnins.2019.00272

  • CrossRef
  • Google Scholar

• 111

  XuM.WanC.-x.HuangS.-h.WangH.-b.FanD.WuH.-M.et al (2019). Oridonin Protects against Cardiac Hypertrophy by Promoting P21-Related Autophagy. Cell Death Dis10, 403. 10.1038/s41419-019-1617-y

  • CrossRef
  • Google Scholar

• 112

  XuT.JinF.WuK.YeZ.LiN.LiN. (2017). Oridonin Enhances In Vitro Anticancer Effects of Lentinan in SMMC-7721 Human Hepatoma Cells through Apoptotic Genes. Exp. Ther. Med.14, 5129–5134. 10.3892/etm.2017.5168

  • CrossRef
  • Google Scholar

• 113

  XuZ.-Z.FuW.-B.JinZ.GuoP.WangW.-F.LiJ.-M. (2016). Reactive Oxygen Species Mediate Oridonin-Induced Apoptosis through DNA Damage Response and Activation of Jnk Pathway in Diffuse Large B Cell Lymphoma. Leuk. Lymphoma57, 888–898. 10.3109/10428194.2015.1061127

  • CrossRef
  • Google Scholar

• 114

  YanY.TanR.-z.LiuP.LiJ.-c.ZhongX.LiaoY.et al (2020). Oridonin Alleviates Iri-Induced Kidney Injury by Inhibiting Inflammatory Response of Macrophages via Akt-Related Pathways. Med. Sci. Monit.26, e921114. 10.12659/MSM.921114

  • CrossRef
  • Google Scholar

• 115

  YangH.GaoY.FanX.LiuX.PengL.CiX. X.et al (2019a). Oridonin Sensitizes Cisplatin-Induced Apoptosis via Ampk/akt/mtor-dependent Autophagosome Accumulation in A549 Cells. Front. Oncol.9, 769. 10.3389/fonc.2019.00769

  • CrossRef
  • Google Scholar

• 116

  YangH.HuangJ.GaoY.WenZ.PengL.CiX. (2020). Oridonin Attenuates Carrageenan-Induced Pleurisy via Activation of the KEAP-1/Nrf2 Pathway and Inhibition of the TXNIP/NLRP3 and NF-κB Pathway in Mice. Inflammopharmacol28, 513–523. 10.1007/s10787-019-00644-y

  • CrossRef
  • Google Scholar

• 117

  YangH.LvH.LiH.CiX.PengL. (2019b). Oridonin Protects LPS-Induced Acute Lung Injury by Modulating Nrf2-Mediated Oxidative Stress and Nrf2-independent NLRP3 and NF-κB Pathways. Cell Commun Signal17, 62. 10.1186/s12964-019-0366-y

  • CrossRef
  • Google Scholar

• 118

  YangI.-H.ShinJ.-A.LeeK.-E.KimJ.ChoN.-P.ChoS.-D. (2017). Oridonin Induces Apoptosis in Human Oral Cancer Cells via Phosphorylation of Histone H2ax. Eur. J. Oral Sci.125, 438–443. 10.1111/eos.12387

  • CrossRef
  • Google Scholar

• 119

  YangY.-C.LinP.-H.WeiM.-C. (2017). Production of Oridonin-Rich Extracts fromRabdosia Rubescensusing Hyphenated Ultrasound-Assisted Supercritical Carbon Dioxide Extraction. J. Sci. Food Agric.97, 3323–3332. 10.1002/jsfa.8182

  • CrossRef
  • Google Scholar

• 120

  YaoZ.XieF.LiM.LiangZ.XuW.YangJ.et al (2017). Oridonin Induces Autophagy via Inhibition of Glucose Metabolism in P53-Mutated Colorectal Cancer Cells. Cel Death Dis8, e2633. 10.1038/cddis.2017.35

  • CrossRef
  • Google Scholar

• 121

  YuT.XieW.SunY. (2019). Oridonin Inhibits LPS-Induced Inflammation in Human Gingival Fibroblasts by Activating PPARγ. Int. Immunopharmacology72, 301–307. 10.1016/j.intimp.2019.04.006

  • CrossRef
  • Google Scholar

• 122

  YuanZ.OuyangP.GuK.RehmanT.ZhangT.YinZ.et al (2019). The Antibacterial Mechanism of Oridonin against Methicillin-Resistant staphylococcus Aureus (Mrsa). Pharm. Biol.57, 710–716. 10.1080/13880209.2019.1674342

  • CrossRef
  • Google Scholar

• 123

  ZangK.-h.ShaoY.-y.ZuoX.RaoZ.QinH.-y. (2016). Oridonin Alleviates Visceral Hyperalgesia in a Rat Model of Postinflammatory Irritable Bowel Syndrome: Role of Colonic Enterochromaffin Cell and Serotonin Availability. J. Med. Food19, 586–592. 10.1089/jmf.2015.3595

  • CrossRef
  • Google Scholar

• 124

  Zhang D.D.ZhouQ.HuangD.HeL.ZhangH.HuB.et al (2019). Ros/jnk/c-jun axis Is Involved in Oridonin-Induced Caspase-dependent Apoptosis in Human Colorectal Cancer Cells. Biochem. Biophysical Res. Commun.513, 594–601. 10.1016/j.bbrc.2019.04.011

  • CrossRef
  • Google Scholar

• 125

  Zhang J.J.ZhouY.SunY.YanH.HanW.WangX.et al (2019). Beneficial Effects of Oridonin on Myocardial Ischemia/reperfusion Injury: Insight Gained by Metabolomic Approaches. Eur. J. Pharmacol.861, 172587. 10.1016/j.ejphar.2019.172587

  • CrossRef
  • Google Scholar

• 126

  Zhang W.W.LuY.ZhenT.ChenX.ZhangM.LiuP.et al (2019). Homoharringtonine Synergy with Oridonin in Treatment of T(8; 21) Acute Myeloid Leukemia. Front. Med.13, 388–397. 10.1007/s11684-018-0624-1

  • CrossRef
  • Google Scholar

• 127

  ZhangY.-w.BaoM.-h.HuL.QuQ.ZhouH.-h. (2014a). Dose-response of Oridonin on Hepatic Cytochromes P450 Mrna Expression and Activities in Mice. J. Ethnopharmacology155, 714–720. 10.1016/j.jep.2014.06.009

  • CrossRef
  • Google Scholar

• 128

  ZhangY.-w.ZhengX.-w.LiuY.-j.FangL.PanZ.-f.BaoM.-h.et al (2018b). Effect of Oridonin on Cytochrome P450 Expression and Activities in Heparg Cell. Pharmacology101, 246–254. 10.1159/000486600

  • CrossRef
  • Google Scholar

• 129

  ZhangY. W.BaoM. H.WangG.QuQ.ZhouH. H. (2014b). Induction of Human Cyp3a4 by Huperzine a, Ligustrazine and Oridonin through Pregnane X Receptor-Mediated Pathways. Pharmazie69, 532–536. 10.1691/ph.2014.3950

  • CrossRef
  • Google Scholar

• 130

  ZhangY.WangS.DaiM.NaiJ.ZhuL.ShengH. (2020). Solubility and Bioavailability Enhancement of Oridonin: A Review. Molecules25, 332. 10.3390/molecules25020332

  • CrossRef
  • Google Scholar

• 131

  ZhangY. W.BaoM. H.LouX. Y.ChengY.YuJ.ZhouH. H. (2018a). Effects of Oridonin on Hepatic Cytochrome P450 Expression and Activities in Pxr-Humanized Mice. Biol. Pharm. Bull.41, 707–712.

  • Google Scholar

• 132

  ZhangZ. Y.DanielsR.SchluesenerH. J. (2013). Oridonin Ameliorates Neuropathological Changes and Behavioural Deficits in a Mouse Model of Cerebral Amyloidosis. J. Cel. Mol. Med.17, 1566–1576. 10.1111/jcmm.12124

  • CrossRef
  • Google Scholar

• 133

  ZhaoG.ZhangT.MaX.JiangK.WuH.QiuC.et al (2017). Oridonin Attenuates the Release of Pro-inflammatory Cytokines in Lipopolysaccharide-Induced raw264.7 Cells and Acute Lung Injury. Oncotarget8, 68153–68164. 10.18632/oncotarget.19249

  • CrossRef
  • Google Scholar

• 134

  ZhaoJ.ZhangM.HeP.ZhaoJ.ChenY.QiJ.et al (2017). Proteomic Analysis of Oridonin-Induced Apoptosis in Multiple Myeloma Cells. Mol. Med. Rep.15, 1807–1815. 10.3892/mmr.2017.6213

  • CrossRef
  • Google Scholar

• 135

  ZhaoY.-J.LvH.XuP.-B.ZhuM.-M.LiuY.MiaoC.-H.et al (2016). Protective Effects of Oridonin on the Sepsis in Mice. Kaohsiung J. Med. Sci.32, 452–457. 10.1016/j.kjms.2016.07.013

  • CrossRef
  • Google Scholar

• 136

  ZhaoY.XiaH. (2019). Oridonin Elevates Sensitivity of Ovarian Carcinoma Cells to Cisplatin via Suppressing Cisplatin-Mediated Autophagy. Life Sci.233, 116709. 10.1016/j.lfs.2019.116709

  • CrossRef
  • Google Scholar

• 137

  ZhengM.ZhuZ.ZhaoY.YaoD.WuM.SunG. (2017). Oridonin Promotes G2/m Arrest in A549 Cells by Facilitating Atm Activation. Mol. Med. Rep.15, 375–379. 10.3892/mmr.2016.6008

  • CrossRef
  • Google Scholar

• 138

  ZhengW.ZhouC.-Y.ZhuX.-Q.WangX.-J.LiZ.-Y.ChenX.-C.et al (2018). Oridonin Enhances the Cytotoxicity of 5-fu in Renal Carcinoma Cells by Inducting Necroptotic Death. Biomed. Pharmacother.106, 175–182. 10.1016/j.biopha.2018.06.111

  • CrossRef
  • Google Scholar

• 139

  ZhengX. C.WuQ. J.SongZ. H.ZhangH.ZhangJ. F.ZhangL. L.et al (2016). Effects of Oridonin on Growth Performance and Oxidative Stress in Broilers Challenged with Lipopolysaccharide. Poult. Sci.95, 2281–2289. 10.3382/ps/pew161

  • CrossRef
  • Google Scholar

• 140

  ZhouL.SunL.WuH.ZhangL.ChenM.LiuJ.et al (2013). Oridonin Ameliorates Lupus-like Symptoms of Mrllpr/lpr Mice by Inhibition of B-Cell Activating Factor (Baff). Eur. J. Pharmacol.715, 230–237. 10.1016/j.ejphar.2013.05.016

  • CrossRef
  • Google Scholar

• 141

  ZhouM.YiY.HongL. (2019). Oridonin Ameliorates Lipopolysaccharide-Induced Endometritis in Mice via Inhibition of the TLR-4/NF-κBpathway. Inflammation42, 81–90. 10.1007/s10753-018-0874-8

  • CrossRef
  • Google Scholar

• 142

  ZhuH. Q.ZhangC.GuoZ. Y.YangJ. M.GuoJ. H.ChenC.et al (2019). Oridonin Induces Mdm2‐p60 to Promote P53‐mediated Apoptosis and Cell Cycle Arrest in Neuroblastoma. Cancer Med.8, 5313–5326. 10.1002/cam4.2393

  • CrossRef
  • Google Scholar

• 143

  ZouB.-h.TanY.-h.DengW.-d.ZhengJ.-h.YangQ.KeM.-h.et al (2020). Oridonin Ameliorates Inflammation-Induced Bone Loss in Mice via Suppressing Dc-Stamp Expression. Acta Pharmacol. Sin42, 744–754. 10.1038/s41401-020-0477-4

  • CrossRef
  • Google Scholar